JP2017514484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514484A5 JP2017514484A5 JP2016565268A JP2016565268A JP2017514484A5 JP 2017514484 A5 JP2017514484 A5 JP 2017514484A5 JP 2016565268 A JP2016565268 A JP 2016565268A JP 2016565268 A JP2016565268 A JP 2016565268A JP 2017514484 A5 JP2017514484 A5 JP 2017514484A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- vertebrate
- matriptase
- gene
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 106
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 77
- 108010091175 Matriptase Proteins 0.000 claims description 50
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 22
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 239000006143 cell culture medium Substances 0.000 claims description 7
- 230000001771 impaired effect Effects 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 206010064571 Gene mutation Diseases 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 238000012224 gene deletion Methods 0.000 claims description 5
- 238000003209 gene knockout Methods 0.000 claims description 5
- 230000030279 gene silencing Effects 0.000 claims description 5
- 238000012226 gene silencing method Methods 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 2
- 108700028369 Alleles Proteins 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 229960000182 blood factors Drugs 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 2
- 230000037433 frameshift Effects 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 230000002797 proteolythic effect Effects 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000000047 product Substances 0.000 description 5
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461985589P | 2014-04-29 | 2014-04-29 | |
| US61/985,589 | 2014-04-29 | ||
| US201461994310P | 2014-05-16 | 2014-05-16 | |
| US61/994,310 | 2014-05-16 | ||
| PCT/IB2015/053110 WO2015166427A2 (en) | 2014-04-29 | 2015-04-29 | Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514484A JP2017514484A (ja) | 2017-06-08 |
| JP2017514484A5 true JP2017514484A5 (enExample) | 2018-06-14 |
| JP6636453B2 JP6636453B2 (ja) | 2020-01-29 |
Family
ID=53682742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565268A Active JP6636453B2 (ja) | 2014-04-29 | 2015-04-29 | 対象のポリペプチドを組換えによって発現するための新規脊椎動物細胞および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11512335B2 (enExample) |
| EP (3) | EP4332231A3 (enExample) |
| JP (1) | JP6636453B2 (enExample) |
| KR (1) | KR102307278B1 (enExample) |
| CN (1) | CN106255749A (enExample) |
| AU (1) | AU2015254913B2 (enExample) |
| CA (1) | CA2947198C (enExample) |
| DK (2) | DK3536776T5 (enExample) |
| ES (2) | ES2968879T3 (enExample) |
| IL (1) | IL248184B (enExample) |
| LT (2) | LT3137595T (enExample) |
| MX (1) | MX368664B (enExample) |
| PL (2) | PL3137595T3 (enExample) |
| PT (2) | PT3137595T (enExample) |
| RU (1) | RU2710726C2 (enExample) |
| SG (1) | SG11201608358VA (enExample) |
| WO (1) | WO2015166427A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4332231A3 (en) | 2014-04-29 | 2024-05-29 | Novartis AG | Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| AU2018290281B2 (en) | 2017-06-22 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use |
| WO2019180607A1 (en) * | 2018-03-19 | 2019-09-26 | Centre For Cellular And Molecular Platforms | A vector, a host cell and a method thereof |
| WO2020081328A1 (en) * | 2018-10-15 | 2020-04-23 | The Regents Of The University Of California | Complement component 1s (c1s) deficient cells for production of vaccines and biopharmaceutical proteins |
| PE20221416A1 (es) | 2019-09-18 | 2022-09-20 | Novartis Ag | Proteinas de fusion nkg2d y sus usos |
| US20210244821A1 (en) | 2020-02-05 | 2021-08-12 | Novartis Ag | Cho cell expressed het il-15 |
| EP4150085A1 (en) * | 2020-05-11 | 2023-03-22 | Genentech, Inc. | Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same |
| CN115551519A (zh) * | 2020-05-11 | 2022-12-30 | 基因泰克公司 | 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法 |
| EP4526462A1 (en) * | 2022-05-19 | 2025-03-26 | Novartis AG | Improved protein production using mirna technology |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| AU572108B2 (en) | 1983-01-19 | 1988-05-05 | Genentech Inc. | Human tpa production using vectors coding for dhfr protein |
| US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US5648254A (en) * | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
| WO1992008796A1 (en) | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
| US5371198A (en) * | 1991-12-16 | 1994-12-06 | Novo Nordisk A/S | Method for protection of proteolysis-susceptible protein during protein production in a fluid medium |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| AU2001278488A1 (en) | 2000-07-25 | 2002-02-05 | Bayer Aktiengesellschaft | Regulation of human matriptase-like serine protease |
| CN100513414C (zh) * | 2001-08-27 | 2009-07-15 | 杰南技术公司 | 进行抗体表达和装配的系统 |
| MXPA05003493A (es) * | 2002-10-02 | 2005-09-30 | Catalyst Biosciences | Metodos para generar y seleccionar proteasas con especificidad alterada. |
| ATE399872T1 (de) | 2003-03-11 | 2008-07-15 | Serono Lab | Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten |
| CN102443627B (zh) * | 2004-08-10 | 2014-10-29 | 加的夫生物学有限公司 | 用于乳腺癌的预后的试剂盒 |
| ATE504602T1 (de) | 2004-12-20 | 2011-04-15 | Amgen Fremont Inc | Für humane matriptase spezifische bindungsproteine |
| US7632509B2 (en) * | 2005-07-19 | 2009-12-15 | Biosante Pharmaceuticals, Inc. | Methods to express recombinant proteins from lentiviral vectors |
| ES2628395T3 (es) | 2007-08-15 | 2017-08-02 | Bayer Pharma Aktiengesellschaft | Anticuerpo regulado por proteasa |
| ES2546086T3 (es) | 2007-12-21 | 2015-09-18 | Novartis Ag | Sistema de selección en un cultivo de células eucariotas basado en un gen receptor de folato unido a la membrana |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| CA2753814C (en) | 2009-02-27 | 2018-07-31 | Novartis Ag | Novel selection vectors and methods of selecting eukaryotic host cells |
| US8722964B2 (en) * | 2009-04-23 | 2014-05-13 | Transposagen Biopharmaceuticals, Inc. | Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes |
| PT2563904E (pt) | 2010-04-26 | 2015-05-12 | Novartis Ag | Meio de cultura de células aperfeiçoado |
| ES2676412T3 (es) | 2011-06-02 | 2018-07-19 | Socpra Sciences Santé Et Humaines S.E.C. | Inhibidores de matriptasa y usos de los mismos contra infecciones por ortomixovirus |
| CN110078827A (zh) * | 2012-04-27 | 2019-08-02 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| SG11201408554QA (en) * | 2012-06-22 | 2015-02-27 | Cytomx Therapeutics Inc | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| EP4332231A3 (en) | 2014-04-29 | 2024-05-29 | Novartis AG | Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest |
| EP3015475A1 (en) * | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
-
2015
- 2015-04-29 EP EP23205296.9A patent/EP4332231A3/en active Pending
- 2015-04-29 PL PL15739327T patent/PL3137595T3/pl unknown
- 2015-04-29 SG SG11201608358VA patent/SG11201608358VA/en unknown
- 2015-04-29 CN CN201580021660.0A patent/CN106255749A/zh active Pending
- 2015-04-29 DK DK19161388.4T patent/DK3536776T5/da active
- 2015-04-29 LT LTEP15739327.3T patent/LT3137595T/lt unknown
- 2015-04-29 DK DK15739327.3T patent/DK3137595T3/da active
- 2015-04-29 CA CA2947198A patent/CA2947198C/en active Active
- 2015-04-29 WO PCT/IB2015/053110 patent/WO2015166427A2/en not_active Ceased
- 2015-04-29 US US15/307,389 patent/US11512335B2/en active Active
- 2015-04-29 ES ES19161388T patent/ES2968879T3/es active Active
- 2015-04-29 KR KR1020167032875A patent/KR102307278B1/ko active Active
- 2015-04-29 PT PT15739327T patent/PT3137595T/pt unknown
- 2015-04-29 LT LTEP19161388.4T patent/LT3536776T/lt unknown
- 2015-04-29 JP JP2016565268A patent/JP6636453B2/ja active Active
- 2015-04-29 EP EP19161388.4A patent/EP3536776B1/en active Active
- 2015-04-29 PT PT191613884T patent/PT3536776T/pt unknown
- 2015-04-29 PL PL19161388.4T patent/PL3536776T3/pl unknown
- 2015-04-29 AU AU2015254913A patent/AU2015254913B2/en active Active
- 2015-04-29 ES ES15739327T patent/ES2731246T3/es active Active
- 2015-04-29 EP EP15739327.3A patent/EP3137595B1/en active Active
- 2015-04-29 MX MX2016014222A patent/MX368664B/es active IP Right Grant
- 2015-04-29 RU RU2016145928A patent/RU2710726C2/ru active
-
2016
- 2016-10-05 IL IL248184A patent/IL248184B/en active IP Right Grant
-
2022
- 2022-10-26 US US17/973,773 patent/US20230323419A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016145928A (ru) | Новые клетки позвоночных и способы рекомбинантной экспрессии интересующего полипептида | |
| JP7061234B2 (ja) | 組換え宿主細胞内での炭素源調節タンパク質産生 | |
| JP2017046717A (ja) | 組み換え法によって生物活性ビタミンｋ依存性タンパク質を製造する方法 | |
| EP2935319B1 (en) | Production of therapeutic proteins in genetically modified mammalian cells | |
| JP2020511954A (ja) | 発現困難タンパク質のための多部位ｓｓｉ細胞 | |
| EP3422845B1 (en) | Rodents having a humanized tmprss gene | |
| JP2016523552A (ja) | 多重プロテアーゼ欠損糸状菌細胞及びその使用方法 | |
| Razaghi et al. | Is Pichia pastoris a realistic platform for industrial production of recombinant human interferon gamma? | |
| RU2016129278A (ru) | Новые эукариотические клетки и способы их получения для рекомбинантной экспрессии представляющего интерес продукта | |
| Masure et al. | Production and characterization of recombinant active mouse gelatinase B from eukaryotic cells and in vivo effects after intravenous administration | |
| CN112105737B (zh) | 生产目标蛋白质的宿主细胞 | |
| JP3570558B2 (ja) | Ｄｎａ断片およびそれを含むベクター、該ベクターによって形質転換された形質転換体、該ベクターを用いる蛋白質の産生方法 | |
| CN106701813A (zh) | 表达载体及其构建方法与应用 | |
| Preininger et al. | Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage | |
| Yun et al. | Suppression of MHC class II expression by human class II trans-activator constructs lacking the N-terminal domain. | |
| Morrison et al. | Differential stability of proteolytically active and inactive recombinant metalloproteinase in Chinese hamster ovary cells | |
| Bahadori et al. | Establishment of stable chinese hamster ovary cell line capable of expressing human recombinant hemopexin: a promising therapeutic modality against hemolytic anemia | |
| EP2633058B1 (en) | Method for mass production of factor vii/viia | |
| CN110229849B (zh) | 时空调控型uPA基因表达非病毒载体及其制备方法和应用 | |
| CN103834660A (zh) | 一种肺组织特异性bpifa3启动子及其应用 | |
| WO2025199346A1 (en) | Antigen binding proteins that bind tmprss4 and methods of use thereof | |
| Gudu | Anther culture and molecular characterization of a floral-derived gene in the diploid species Hordeum bulbosum L. | |
| HK40033661A (en) | Host cell for producing a protein of interest | |
| HK40057446A (en) | Rodents having a humanized tmprss gene | |
| Heusel | Structural and functional analyses of clustered serine protease genes in humans and mice |